Cresset Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Cresset Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-26	Closed	-$1K	–	1796
2019 Q1	$1K	Hold	26	–	–	﹤0.01%	1908
2018 Q4	$1K	Buy	+26	New	+$1.34K	﹤0.01%	1635

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cresset Asset Management's EGRX Position: Q2 2019 in Review

Cresset Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 26 shares — an estimated $1K sold.

Cresset Asset Management first reported a position in EGRX in Q4 2018 and held it in 2 quarters. The position peaked at $1K in Q1 2019. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

Cresset Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Cresset Asset Management sold 26 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $1K.
Cresset Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
Cresset Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $1K in Q1 2019.
180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on Cresset Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.